HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

B-cell maturation antigen, a proliferation-inducing ligand, and B-cell activating factor are candidate mediators of spinal cord injury-induced autoimmunity.

Abstract
Autoimmunity is thought to contribute to poor neurological outcomes after spinal cord injury (SCI). There are few mechanism-based therapies, however, designed to reduce tissue damage and neurotoxicity after SCI because the molecular and cellular bases for SCI-induced autoimmunity are not completely understood. Recent groundbreaking studies in rodents indicate that B cells are responsible for SCI-induced autoimmunity. This novel paradigm, if confirmed in humans, could aid in the design of neuroprotective immunotherapies. The aim of this study was to investigate the molecular signaling pathways and mechanisms by which autoimmunity is induced after SCI, with the goal of identifying potential targets in therapies designed to reduce tissue damage and inflammation in the chronic phase of SCI. To that end, we performed an exploratory microarray analysis of peripheral blood mononuclear cells to identify differentially expressed genes in chronic SCI. We identified a gene network associated with lymphoid tissue structure and development that was composed of 29 distinct molecules and five protein complexes, including two cytokines, a proliferation-inducing ligand (APRIL) and B-cell-activating factor (BAFF), and one receptor, B-cell maturation antigen (BMCA) involved in B cell development, proliferation, activation, and survival. Real-time polymerase chain reaction analysis from ribonucleic acid samples confirmed upregulation of these three genes in SCI. To our knowledge, this is the first report that peripheral blood mononuclear cells produce increased levels of BAFF and APRIL in chronic SCI. This finding provides evidence of systemic regulation of SCI-autoimmunity via APRIL and BAFF mediated activation of B cells through BMCA and points toward these molecules as potential targets of therapies designed to reduce neuroinflammation after SCI.
AuthorsJonah W Saltzman, Ricardo A Battaglino, Loise Salles, Prateek Jha, Supreetha Sudhakar, Eric Garshick, Helen L Stott, Ross Zafonte, Leslie R Morse
JournalJournal of neurotrauma (J Neurotrauma) Vol. 30 Issue 6 Pg. 434-40 (Mar 15 2013) ISSN: 1557-9042 [Electronic] United States
PMID23088438 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, U.S. Gov't, Non-P.H.S.)
Chemical References
  • B-Cell Activating Factor
  • B-Cell Maturation Antigen
  • Ligands
  • TNFSF13B protein, human
  • Tumor Necrosis Factor Ligand Superfamily Member 13
Topics
  • Adult
  • Aged
  • Autoimmunity (physiology)
  • B-Cell Activating Factor (physiology)
  • B-Cell Maturation Antigen (physiology)
  • B-Lymphocytes (immunology)
  • Cell Proliferation
  • Humans
  • Ligands
  • Male
  • Middle Aged
  • Signal Transduction (physiology)
  • Spinal Cord Injuries (immunology, pathology)
  • Tumor Necrosis Factor Ligand Superfamily Member 13 (physiology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: